<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02431663</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT number: 2013-004396-12</org_study_id>
    <nct_id>NCT02431663</nct_id>
  </id_info>
  <brief_title>Ketamine in Refractory Convulsive Status Epilepticus</brief_title>
  <acronym>KETASER01</acronym>
  <official_title>Efficacy of Ketamine in Refractory Convulsive Status Epilepticus in Children: a Multicenter, Randomized, Controlled, Open-label, No-profit, With Sequential Design Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meyer Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ospedali Riuniti Ancona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IRCCS Azienda Ospedaliero-Universitaria di Bologna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Padova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bambino Ges√π Hospital and Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IRCCS Burlo Garofolo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera Universitaria Integrata Verona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nuovo Regina Margherita Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vittore Buzzi Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Meyer Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of intravenous administration of ketamine in the treatment of&#xD;
      refractory convulsive status epilepticus in children compared to administration of midazolam&#xD;
      at high doses, thiopental and / or propofol.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Futility&#xD;
  </why_stopped>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">March 31, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with resolution of refractory convulsive status epilepticus</measure>
    <time_frame>participant wil be followed for 24 hours after discontinuation of study drug</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Status Epilepticus</condition>
  <arm_group>
    <arm_group_label>ketamine up to 100 mcg/kg/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two intravenous boluses of 2-3 mg/kg each of ketamine will be administered 5 minutes apart and immediately followed by a continuous infusion of 5-10 mcg/kg/min. Based on both clinical or electrographic responses, dosage will be increased every 10 minutes or longer, using 2 to 10 mcg/kg/ min increments, up to 60 mcg/kg/min. Maximum duration of infusion will be of 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>midazolam &amp; thiopental &amp; propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Midazolam intravenous will be increased every 5 minutes, using 2 mcg/kg/min increments, up to 12 mcg/kg/min and Thiopental intravenous will be increased every 30 minutes or longer, using 1 mg/kg/h increments, up to 6 mg/kg/h and Propofol intravenous will be increased every 5 minutes or longer, using 1 mg/kg/h increments, up to 5 mg/kg/h.&#xD;
Maximum duration of infusion for each drug will be 48 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Intravenous administration in continuous</description>
    <arm_group_label>ketamine up to 100 mcg/kg/min</arm_group_label>
    <arm_group_label>midazolam &amp; thiopental &amp; propofol</arm_group_label>
    <other_name>KETAMINA MOLTENI, vials of 2 ml (50 mg/ml)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis and clinical EEGrafica of refractory convulsive status epilepticus&#xD;
&#xD;
          -  Refractoriness of the drug I and II line&#xD;
&#xD;
          -  Written informed consent from parents or legal guardian.&#xD;
&#xD;
          -  Administration of rating scales in the risk of mortality (PIM III) and severity of SE&#xD;
             (stess, status epilepticusseverity score) to be performed prior to randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  contraindications to the use of the medication/s in the study.&#xD;
&#xD;
          -  pregnant or suspected pregnant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Rosati, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital A. Meyer of Firenze, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anna Rosati</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 3, 2015</study_first_submitted>
  <study_first_submitted_qc>April 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2015</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Meyer Children's Hospital</investigator_affiliation>
    <investigator_full_name>Anna Rosati</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>refractory convulsive status epilepticus</keyword>
  <keyword>ketamine</keyword>
  <keyword>conventional anesthetics</keyword>
  <keyword>children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Status Epilepticus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

